Filtered By:
Drug: Cilostazol

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 208 results found since Jan 2013.

The Latest Information on Intracranial Atherosclerosis: Diagnosis and Treatment
Intracranial atherosclerotic stenosis (ICAS) is the most common cause of ischemic stroke in the world. ICAS is especially common in the Asian population accounting for 30-50% of all ischemic strokes. The risk of recurrent stroke in patients with symptomatic ICAS is the highest among the stroke subtypes. Two major factors associated with recurrent stroke are high degree (>70%) of stenosis and progression of ICAS. Transcranial Doppler ultrasound, CT angiography, MR angiography, and conventional catheter angiography are used for the diagnosis of ICAS. Today, high-resolution MRI can provide important information to improve the...
Source: Interventional Neurology - September 18, 2015 Category: Neurology Source Type: research

Antiplatelet Therapy in Cerebral Small Vessel Disease
AbstractPurpose of ReviewWe critically evaluate the evidence for the use of antiplatelet therapy for stroke prevention following lacunar stroke and in patients with hemorrhage-prone cerebral small vessel disease.Recent FindingsPooled lacunar stroke subgroup analyses of all relevant randomized controlled trials to date suggest a 22% relative risk reduction in recurrent stroke by single antiplatelet therapy (RR 0.77, 95% CI 0.62 –0.97) compared with placebo, no consistent suggestion of variable efficacy amongst specific antiplatelet agents, and the absence of clear benefit with dual over single antiplatelet therapy. Curren...
Source: Current Neurology and Neuroscience Reports - July 26, 2019 Category: Neuroscience Source Type: research

Long-Term Effectiveness of Cilostazol in Patients with Hemodialysis with Peripheral Artery Disease
CONCLUSION: Continuous treatment of cilostazol in patients with HD with PAD significantly decreases the risk of ED visits, hemorrhagic stroke, and cardiovascular events and improves ED visit-free and cardiovascular event-free rates during long-term follow-up.PMID:36216573 | DOI:10.5551/jat.63404
Source: Journal of Atherosclerosis and Thrombosis - October 10, 2022 Category: Cardiology Authors: Chung-Kuan Wu Chia-Hsun Lin Noi Yar Zih-Kai Kao Ya-Bei Yang Yun-Yi Chen Source Type: research

Meta-Analysis of Studies Evaluating the Effect of Cilostazol on Major Outcomes After Carotid Stenting
Conclusion: Cilostazol seems to decrease total ISR rates in patients undergoing CAS without affecting MI/stroke/death events, both in the early and late settings.
Source: Journal of Endovascular Therapy - January 12, 2016 Category: Surgery Authors: Galyfos, G., Geropapas, G., Sigala, F., Aggeli, K., Sianou, A., Filis, K. Tags: Carotid Artery Stenting Source Type: research

Antithrombotic Therapy.
Authors: Kwon SU, Kim JS Abstract Symptomatic cerebral atherosclerosis including intracranial atherosclerosis (ICAS) is associated with a high risk of recurrent stroke. Antithrombotic agents are the mainstay of therapy in these patients. Several studies have found anticoagulation (warfarin) to increase the risk of bleeding events and have an efficacy no better than that of aspirin. Therefore, anticoagulants are not widely used unless patients develop recurrent ischemic symptoms despite receiving antiplatelet therapy. Because ICAS progression is not uncommon and the risk of stroke recurrence is high when aspirin mon...
Source: Frontiers of Neurology and Neuroscience - December 15, 2016 Category: Neuroscience Tags: Front Neurol Neurosci Source Type: research

Cilostazol-based dual anti-platelet agents for Asian patients: An updated network meta-analysis
Antiplatelet therapy, including aspirin, has been used for the secondary prevention of non-cardioembolic ischemic stroke [1]. Because patients who have a higher risk of recurrent stroke need antiplatelet agents with higher efficacy than aspirin, dual antiplatelet therapy (DAPT) has been used in cases requiring higher efficacy, such as the acute stage of stroke or high-risk patients [2]. However, DAPT is notably associated with an increased risk of bleeding like a two-edged sword [3]. Aspirin plus clopidogrel is recommended for a few weeks after acute ischemic stroke, preventing bleeding risk from not exceeding the power of...
Source: Journal of the Neurological Sciences - October 8, 2022 Category: Neurology Authors: Seung Jin Jung, Sung Ryul Shim, Bum Joon Kim, Jin-Man Jung Source Type: research

Antiplatelets and Vascular Dementia: A Systematic Review
J Aging Res. 2022 Sep 19;2022:9780067. doi: 10.1155/2022/9780067. eCollection 2022.ABSTRACTVascular dementia (VD) is a neurocognitive disorder whose precise definition is still up for debate. VD generally refers to dementia that is primarily caused by cerebrovascular disease or impaired cerebral blood flow. It is a subset of vascular cognitive impairment, a class of diseases that relate any cerebrovascular injury as a causal or correlating factor for cognitive decline, most commonly seen in the elderly. Patients who present with both cognitive impairment and clinical or radiologic indications of cerebrovascular pathology s...
Source: Journal of Aging Research - October 17, 2022 Category: Geriatrics Authors: Peter Alexander Shakthi Visagan Sara Jawhar Amogh Kare Noor Issa Reem Issa Abbas Jawhar Sneha Thomas Vasavi Gorantla Source Type: research

Treatment with cilostazol improves clinical outcome after endovascular therapy in hemodialysis patients with peripheral artery disease.
CONCLUSIONS: Cilostazol administration improves long-term clinical outcomes including prevention of MACE and stroke after endovascular therapy in HD patients with PAD. PMID: 26074442 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - June 11, 2015 Category: Cardiology Authors: Ishii H, Aoyama T, Takahashi H, Kumada Y, Kamoi D, Sakakibara T, Umemoto N, Suzuki S, Tanaka A, Ito Y, Murohara T Tags: J Cardiol Source Type: research